Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Food insecurity is not only linked with, but directly causes symptoms of anxiety and depression, according to research published in the open access ...

Johnson & Johnson boosted its full-year outlook as it posted better-than-expected profit and sales in the second quarter. The healthcare-products company said Tuesday it now expects adjusted per-share ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

Adjusted earnings per share for the quarter to June 29 fell to $2.77 from $2.82 in the same period a year ago, and topped the ...

Johnson & Johnson shares surged Wednesday after the company reported second-quarter results that topped estimates and the company lifted its full-year outlook.

Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and ...

Johnson & Johnson (NYSE:JNJ) reported Q2 2025 earnings on July 16, 2025, posting sales of $23.7 billion (up 4.6%), with adjusted EPS of $2.77 and net earnings of $5.5 billion. Management raised ...

Discover Johnson & Johnson's Q2 2025 earnings insights with raised guidance and strategic growth in Oncology & MedTech.

Invest 93-L continues to move westward across the Gulf Coast and is producing disorganized showers and thunderstorms, according to the National Hurricane Center. The system is expected to continue ...

For decades, proponents of psychedelic drugs have come to Washington with a provocative message: Illegal, mind-altering substances like LSD and ecstasy should be approved for Americans grappling with ...